Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Mar 28;14:1116057. doi: 10.3389/fimmu.2023.1116057

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2023 Yan, Zhang, Chen, Lu, Huang, Cai, Chen, Bei, Bai, Lv, Fu and Zhang

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

MR images and the timeline of therapy in three cases with HPD. (A) Case 1. Pre-baseline MR was obtained before ablation. After confirmed progression 5 months later, the patient adopted immunotherapy. Evaluation scan after 1.8 months showed significant radiological progression of disease with occurrence of new lesions. The TGR fold was calculated to be 11.90. (B) Case 2. After 2 cycles of immunotherapy, MR showed significant progression of intra-hepatic lesions. TTF was 1.6 months. TBI was 579.5%. (C) Case 3. After 2 cycles of treatment, MR scan showed significant progression of disease with increase in size of hepatic lesions. TTF was 1.3 months. TBI was 53.5%.